Physician profile
Jon E Berner
NPI 1518042282
$1,592.55
in general payments reported to CMS, 2019-2025
19 companies · $71.34 in 2025
The $71.34 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $290 · 2021: $93.68 · 2022: $94.95 · 2023: $120 · 2024: $108 · 2025: $71.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $298.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $254.86 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $249.48 | 2019-2025 | |
| Allergan, INC. | $171.48 | 2019-2020 | |
| Neuronetics, INC. | $168.41 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $114.65 | 2019 | |
| Idorsia Pharmaceuticals US INC | $107.56 | 2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $106.75 | 2019-2023 | |
| Lundbeck LLC | $102.66 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.33 | 2019-2020 | |
| Shire North American Group INC | $61.50 | 2019 | |
| Avanir Pharmaceuticals, INC. | $38.67 | 2019 | |
| Ironshore Pharmaceuticals INC. | $35.20 | 2019 | |
| Tris Pharma INC | $21.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $20.41 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.58 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $13.97 | 2023 | Latuda |
| Adlon Therapeutics L.P. | $13.56 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.46 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Berner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.